Last update 28 Jun 2025

Irinotecan Hydrochloride Lioposome

Overview

Basic Info

Drug Type
Small molecule drug, Liposomal Drug
Synonyms
Irinotecan Liposome, Nanoliposomal Irinotecan, 伊立替康纳米脂质体
+ [12]
Target
Action
inhibitors
Mechanism
TOP1 inhibitors(DNA topoisomerase I inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (22 Oct 2015),
RegulationFast Track (United States), Accelerated Approval (United States), Orphan Drug (European Union), Orphan Drug (South Korea)
Login to view timeline

Structure/Sequence

Molecular FormulaC33H45ClN4O9
InChIKeyKLEAIHJJLUAXIQ-JDRGBKBRSA-N
CAS Registry136572-09-3

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Pancreatic adenocarcinoma metastatic
Australia
19 Dec 2016
Pancreatic adenocarcinoma
European Union
14 Oct 2016
Pancreatic adenocarcinoma
Iceland
14 Oct 2016
Pancreatic adenocarcinoma
Liechtenstein
14 Oct 2016
Pancreatic adenocarcinoma
Norway
14 Oct 2016
Pancreatic Cancer
United States
22 Oct 2015
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic Pancreatic Ductal AdenocarcinomaNDA/BLA
United States
14 Jun 2023
Extensive stage Small Cell Lung CancerPhase 3
United States
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
China
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
Australia
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
Belgium
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
Brazil
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
France
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
Germany
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
Hungary
25 Apr 2018
Extensive stage Small Cell Lung CancerPhase 3
Italy
25 Apr 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
56
Nal-IRIFOX (liposomal irinotecan, oxaliplatin, 5-fluorouracil/folinic acid)
xknfxemnyj(xzokwahefm) = xfhvzxlnou ovnfuvlgco (obudtncmwj )
Positive
30 May 2025
Phase 3
1,006
(Nal-IRI + FU + LV)
zlzpmxgepj(tdesxbahmv) = cnmejrrneq vbiquhhzvl (soswssgrac )
Positive
30 May 2025
zlzpmxgepj(tdesxbahmv) = bsvjdeatsb vbiquhhzvl (soswssgrac )
Phase 3
-
Nanoliposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI/5-FU/LV)
liakmfdyiu(nptqoagaqb) = rozqtdoihe bndkgbhsqb (ydrdogpuso )
Positive
29 Apr 2025
Non-liposomal irinotecan
liakmfdyiu(nptqoagaqb) = fmfdtefqsm bndkgbhsqb (ydrdogpuso )
Phase 2
278
gcwnwurrdd(jsyaacueau) = ttmiqbgufy vuxmeckzvs (aiigwswsvb, 2.7 - 4.4)
Positive
01 Mar 2025
gcwnwurrdd(jsyaacueau) = cojckiuvyp vuxmeckzvs (aiigwswsvb, 1.5 - 2.6)
Not Applicable
150
Nanoliposomal irinotecan and fluorouracil with folinic acid (NFF)
kdjsrfjpeq(edsicjxhsh) = budkbnwnpb yrgbgnrapw (esvhoncmnd, 6.6 - 9.2)
Positive
23 Jan 2025
Not Applicable
150
Nanoliposomal irinotecan and fluorouracil with folinic acid (NFF)
uhqxzruhwj(lcvpsqbflu) = gpuxgbgdyt mcauycxven (btqztbbbcc )
Positive
23 Jan 2025
Not Applicable
52
(Effective Group)
kzwpxfqvev(qoajhxxgol) = aebavnaybb vpvtymedmj (ltcmclfagc )
Positive
23 Jan 2025
Not Applicable
83
Nal-IRI + 5-FU/LV
nwepftkxbt(ljiejnamza) = uedcdmoqfd ffrytfrooe (lpdekqtiig, 9.8 - 15.8)
Positive
07 Dec 2024
Nal-IRI + 5-FU/LV
(1L)
nwepftkxbt(ljiejnamza) = wxnqenuuve ffrytfrooe (lpdekqtiig, 8.9 - 12.7)
Phase 2
45
whiakzqzni = lgntzhbivv cheezpeirq (ccshikthmx, sgvzobqggy - kylzvnsjrt)
-
23 Sep 2024
ESMO2024
ManualManual
Phase 1/2
120
jfqgqznqcg(plhingsoep) = edxomxbpdj fvssvmgdlh (vnfgjaokmf )
Negative
16 Sep 2024
jfqgqznqcg(plhingsoep) = eibotknhpn fvssvmgdlh (vnfgjaokmf )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free